Boehringer Ingelheim patents KRAS G12C mutant inhibitors for the treatment of cancer
July 20, 2023
Boehringer Ingelheim Pharma GmbH & Co. KG has prepared and tested heteroaromatic compounds described as GTPase KRAS G12C mutant inhibitors and reported to be useful for the treatment of cancer.